A universal flu vaccine may be in sight
21 September 2018 | By Iqra Farooq (Drug Target Review)
Researchers from Oxford have identified the initial steps on the path towards creating a universal influenza vaccine that could last for life...
List view / Grid view
Informatics
ELRIG UK Drug Discovery 2018 Event
19 September 2018 | By ELRIG
ELRIG’s (European Laboratory Research & Innovation Group) Drug Discovery meeting, will take place at ExCeL, London, UK, located in the heart of the city, from 9 -10 October 2018...
Timing could be crucial when taking medication
14 September 2018 | By Iqra Farooq (Drug Target Review)
Researchers used a bioinformatic tool to suggest that circadian timing could be key to the success of certain drugs or therapies...
Synthetic biology in drug discovery
13 September 2018 | By Dr Tim Brears - Chief Executive Officer - Evonetix
Synthetic biology is broadly defined as the design and construction of novel artificial biological pathways, organisms or devices; or the redesign of existing natural biological systems.1 It brings together a range of disciplines and skills, from biology and chemistry to computing, bioinformatics and engineering.
Expert view: Challenges in flow cytometry
11 September 2018 | By John O'Rouke (Sartorius)
Flow cytometry is a powerful and flexible technology that delivers high content information from single cells and particles. Flow cytometry lends itself to a wide variety of applications, but traditional flow cytometry technologies are not widely adopted in the drug discovery industry due to limited throughput, slow sampling speeds and…
Expert view: Generate high‑content information using flow cytometry
11 September 2018 | By Yannick Marrari (Bio-Rad)
Flow cytometry has become a widely used technology in life science research since its development in the 1970s. It is also essential for many biopharmaceutical and biotechnology companies due to its proficiency in identifying biomarkers, finding new inhibitory antibodies, and assessing the efficiency of new pharmacological protocols.
Expert view: Tools for compliance with 21 CFR Part 11
11 September 2018 | By Maria C. Gentile (Beckman Coulter)
All computer systems that store data to make Quality decisions or data that will be reported to the FDA must be compliant with 21 CFR Part 11. The purpose of this law is to define the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent…
A new generation of pain relief
10 September 2018 | By Drug Target Review
Researchers have developed a new generation of pain relief drugs that only target the affected area, with the help of computer simulations...
Expert view: Screen everything. See everything.
10 September 2018 | By Yasmina Noubia Abdiche (Carterra)
Explore the full kinetic and epitope diversity of large antibody libraries with high throughput Array SPR (Surface Plasmon Resonance).
Flow Cytometry In-Depth Focus 2018
7 September 2018 | By Drug Target Review
Flow cytometry has played a key role in drug development, largely due to its ability to measure up to twenty parameters on single cells or particles suspended in a fluid stream. Conor Fitzpatrick discusses how the rise of high-throughput flow cytometry has contributed to the advancements in drug discovery...
Expert view: GMP proteins for therapeutic manufacturing: combining consistency, safety, and supply
6 September 2018 | By Tim Manning (Bio-Techne)
Cell therapies offer revolutionary new approaches for treating humandisease. Most of these treatments use GMP cytokines and growthfactors for the differentiation, expansion, and maintenance of cells.It is critical that GMP protein suppliers offer the optimal combinationof consistency, safety, and stable supply chain.
Application Note: Evaluating the specificity and potency of PD-1 and PD-L1 blocking antibodies using AlphaLISA human and mouse PD-1/PD-L1 binding kits
5 September 2018 | By Cat Lautenschlager, Dawn Nida, Jeanine Hinterneder, Lauren Berstler
Cancer immunotherapy utilises components of the immune system to treat cancer patients. These therapies are designed to work with a patient’s immune system to increase native anti-tumour responses. One type of immunotherapy relies on antibodies to bind to and inhibit the function of proteins expressed by the cancer cell...
How challenges including Brexit, inadequate funding & insufficient sample sizes hinder rare disease research
4 September 2018 | By SMi Group
SMi Reports: 8th Annual Orphan Drugs and Rare Diseases Conference to bring together pharmaceutical companies, non-profit organisations and orphan drug developers to explore alliances and facilitate progress.
Researchers successfully use AI to facilitate dynamic dosing for metastatic cancer
4 September 2018 | By Drug Target Review
Scientists have harnessed a powerful artificial intelligence (AI) platform, CURATE.AI, to successfully treat a patient with advanced cancer by completely halting disease progression, representing a big step forward in personalised medicine.
Computational analysis identifies a new clinical phenotype of severe malaria
4 September 2018 | By Drug Target Review
Researchers have applied a computational analysis based on networks in order to identify biologically relevant phenotypes apart from those currently defined by the WHO...
Follow: